Literature DB >> 31799684

Effect of SOCS3 on lung injury in rats with severe acute pancreatitis through regulating JAK2/STAT3 signaling pathway.

M-Z Qin1, M-B Qin, Z-H Liang, G-D Tang.   

Abstract

OBJECTIVE: To explore the effect of suppressor of cytokine signaling 3 (SOCS3) on the lung injury in rats with severe acute pancreatitis (SAP) by regulating the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway.
MATERIALS AND METHODS: Sprague-Dawley rats were divided into control group (n=20) and SAP model group (established via injection of 5% sodium taurocholate, n=40). Then, SOCS3 was overexpressed using the adenovirus in 20 rats in SAP model group. The serum amylase (AMY) was detected, whether the transfection was successful was verified via quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR), the hepatic function indexes were detected, the pathological changes were observed using hematoxylin-eosin (HE) staining, and the wet/dry weight ratio (W/D) was calculated. Moreover, the content of serum inflammatory factors was detected via enzyme-linked immunosorbent assay (ELISA) and the expression levels of JAK2/STAT3 signaling pathway genes and proteins were detected through RT-PCR and Western blotting.
RESULTS: The content of AMY in SAP model group was significantly increased, indicating the successful modeling. SOCS3 was significantly increased in transfection group, suggesting that the transfection efficiency was significant. The content of alanine aminotransferase (ALT),  and aspartate aminotransferase (AST) in SOCS3 transfection group was significantly lower than in model group. According to the histopathological observation, there were lung injury, pulmonary edema, hemorrhage, severe inflammatory response, and alveolar congestion in SAP model group. There were almost no pathological changes in SOCS3 transfection group. In SOCS3 transfection group, the content of serum interleukin-6 (IL-6), IL-18 and tumor necrosis factor-α (TNF-α), the mRNA and protein expressions of IL-6, JAK2, and STAT3 were all remarkably declined.
CONCLUSIONS: SOCS3 inhibits the activation of the JAK2/STAT3 pathway and the increase of inflammatory factors, promoting the repair of lung injury in SAP rats.

Entities:  

Year:  2019        PMID: 31799684     DOI: 10.26355/eurrev_201911_19582

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Chimeric Peptidomimetics of SOCS 3 Able to Interact with JAK2 as Anti-inflammatory Compounds.

Authors:  Sara La Manna; Laura Lopez-Sanz; Flavia Anna Mercurio; Sara Fortuna; Marilisa Leone; Carmen Gomez-Guerrero; Daniela Marasco
Journal:  ACS Med Chem Lett       Date:  2020-03-19       Impact factor: 4.345

2.  Dysregulated B7H4/JAK2/STAT3 Pathway Involves in Hypertriglyceridemia Acute Pancreatitis and Is Attenuated by Baicalin.

Authors:  Jie Yang; Fei Han; Guanghai Wu; Ya Dong; Hang Su; Jing Xu; Jun Li
Journal:  Dig Dis Sci       Date:  2022-07-04       Impact factor: 3.199

3.  Genome-wide expression of the residual lung reacting to experimental Pneumonectomy.

Authors:  Valerio Napolioni; Fortunato Bianconi; Rossella Potenza; Francesco M Carpi; Vienna Ludovini; Matteo Picciolini; Francesca R Tofanetti; Antonello Bufalari; Stefano Pallotti; Camilla Poggi; Marco Anile; Niccolò Daddi; Federico Venuta; Francesco Puma; Jacopo Vannucci
Journal:  BMC Genomics       Date:  2021-12-06       Impact factor: 3.969

4.  Spectrum effect correlation of yangyin tongnao granules on cerebral ischemia-reperfusion injury rats.

Authors:  Yangyang Zhang; Li Yu; Jiehong Yang; Zhishan Ding; Yu He; Haitong Wan
Journal:  Front Pharmacol       Date:  2022-08-09       Impact factor: 5.988

5.  Protective effect of anisodamine on bleomycin-induced acute lung injury in immature rats via modulating oxidative stress, inflammation, and cell apoptosis by inhibiting the JAK2/STAT3 pathway.

Authors:  Xiaoqi Zhao; Bin Zhao; Yinghao Zhao; Yunfeng Zhang; Min Qian
Journal:  Ann Transl Med       Date:  2021-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.